



Supplementary figure 1a. Breadth of T-cell response toward different structural viral proteins (S, M, N) in convalescent (red bars) and HCWs with cross-reactive immunity (blue bars). SMN, response to the three viral proteins; S+, presence of response to protein S (at least); M+, presence of response to M; N+, response to N.




Suppl Figure 2. Cumulative percentage and type of adverse events after 1st dose of vaccination according to baseline immune status: cross-reactive immunity (CR), non-reactive (NR), convalescent with persistence of antibodies (Cab+) and recovered HCWs with loss of antibodies during follow up (Cab-). The number of individuals in each group is shown below the graphs.

SARS-Cov-2 peptide S



Suppl Figure 3a. Dose-response curves in six samples for peptide concentrations of 0.5, 1, 1.5, and 2 $\mu\text{g mL}^{-1}$ in SARS-CoV-2 peptide pool S. A concentration of 1 $\mu\text{g mL}^{-1}$ was chosen.



Supplementary figure 3b. Flow cytometry strategy